Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: A prospective observational study

International Journal of Cardiology

Volumn 169, Issue 4, 2013, Pages 271-275

  Grimaldi Bensouda, Lamiae ^a,b,c   Rossignol, Michel ^d,e   Danchin, Nicolas ^f,g   Dallongeville, Jean ^h,i   Bruckert, Eric ^j,k   Banayan, Jonathan ^l   Cottin, Yves ^m   Aubrun, Elodie ^a   Khachatryan, Artak ⁿ   Bénichou, Jacques ^o,p   Abenhaim, Lucien ^n,q  

^a LA SER   (France)

^b Bioinformatique et Chimie Moléculaire   (France)

^c INSTITUT PASTEUR   (France)

^d LA SER Center for Risk Research   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h INSTITUT PASTEUR DE LILLE   (France)

ⁱ INSERM   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k SORBONNE UNIVERSITÉ   (France)

^l SERVICE DE DERMATOLOGIE   (France)

^m DIJON UNIVERSITY HOSPITAL   (France)

ⁿ London School of Hygiene Tropical Medicine   (United Kingdom)

^o ROUEN UNIVERSITY HOSPITAL   (France)

^p INSERM U657   (France)

^q LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

Acute coronary syndrome; Case control study; Effectiveness; Epidemiology; Real life; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK REDUCTION; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; CASE-CONTROL STUDY; EFFECTIVENESS; EPIDEMIOLOGY; REAL LIFE; STATINS;

ACUTE CORONARY SYNDROME; AGED; CASE-CONTROL STUDIES; FEMALE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 84887432486     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.127     Document Type: Article

References (20)

1. Cholesterol Treatment Trialists' (CTT) Collaborators B. Mihaylova, and J. Emberson The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
2. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, and L. Blackwell Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. F. Taylor, K. Ward, and T.H. Moore Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2011 CD004816
4. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
5. P. Verdecchia, G. Reboldi, and F. Angeli Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention Hypertension 46 2005 386 392
6. L.H. Lindholm, B. Carlberg, and O. Samuelsson Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 2005 1545 1553
7. N. Khan, and F.A. McAlister Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis Can Med Assoc J 174 2006 1737 1742
8. E.Z. Fisman, A. Tenenbaum, and M. Motro Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint Herz 29 2004 290 298
9. L. Abenhaim, Y. Moride, and F. Brenot Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group N Engl J Med 335 1996 609 616
10. L. Grimaldi-Bensouda, M. Rossignol, and N. Danchin Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs Heart 97 2011 1834 1840
11. L. Grimaldi-Bensouda, M. Rossignol, and E. Aubrun Agreement between patients' self-report and physicians' prescriptions on cardiovascular drug exposure: the PGRx database experience Pharmacoepidemiol Drug Saf 19 2010 591 595
12. M. Hanssen, Y. Cottin, and K. Khalife French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. FAST-MI 2010 Heart 98 2012 699 705
13. C.R. Dormuth, A.R. Patrick, and W.H. Shrank Statin adherence and risk of accidents: a cautionary tale Circulation 119 2009 2051 2057
14. Direction des études, des évaluations et des statistiques (DRESS) Statistical report on consultations with general practitioners in France] (in French) Études et résultats 315: 1-11 http://www.drees.sante.gouv.fr/IMG/pdf/er315.pdf 2004
15. C.P. Cannon, B.A. Steinberg, and S.A. Murphy Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
16. M.E. Bertrand, M.L. Simoons, and K.A. Fox Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 23 2002 1809 1840
17. J. López-Sendón, K. Swedberg, and J. McMurray Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology Eur Heart J 25 2004 1454 1470
18. C. Patrono, F. Bachmann, and C. Baigent The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology Eur Heart J 25 2004 166 181
19. I. Graham, D. Atar, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice: executive summary Atherosclerosis 194 2007 1 45
20. F. Delahaye, M. Bory, and A. Cohen Recommendations of the French Society of Cardiology concerning the treatment of myocardial infarction after the acute phase. Epidemiology and Prevention Group Arch Mal Coeur Vaiss 94 2001 697 738